Clinical Trial Update: Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of fesoterodine in pediatric patients (ages 8-17) with overactive bladder or neurogenic detrusor overactivity has been completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Overactive Bladder

Drugs mentioned

• Fesoterodine (Toviaz) (fesoterodine)

Snippet

Sponsor: Pfizer | Conditions: Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 2 | Status: COMPLETED | Results posted: 2011-11-17